LanaAI launches phase two of testing, introducing new US stock asset strategies
Odaily reported that Rana AI has disclosed its latest operational status. The first phase of testing started with 100U, and the account grew to a maximum of 300,000U, with cumulative profits withdrawn totaling 40,000U. Subsequently, the account’s net value experienced a drawdown to approximately 20,000U.
Currently, Rana AI has launched the second phase of strategy testing, using 20,000U as the new starting point. Building on the original crypto asset trading strategies, it has added U.S. stock asset strategies to validate the performance and sustainability of its cross-market trading model.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma
GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.
Germany's DAX 40 fell to 25,200 points, down 0.8% in 24 hours
Borr Drilling Divests Mexican Oil Drilling Joint Ventures
Altares says French firms cut average payment delays to 12.3 days in H1 2026
Crypto prices
More
